Heritage Health Services Medicare and Medicaid Location: 1119 N Wisconsin St, Port Washington, Wisconsin 53074 Ratings: Phone: (262) 284-5892 |
News Archive
This week is the International Week of the Deaf, held to draw attention to deaf and hearing-impaired people, their accomplishments and challenges they face. One health care issue is a potential communication barrier between medical providers and deaf or hard-of-hearing patients.
The National Institutes of Health has awarded a three-year, $2.6-million grant to the University of South Florida and Tampa-based biotechnology company Saneron-CCEL Therapeutics, Inc., to establish dosing and safety guidelines for transplanting human umbilical cord blood cells (HUBC) into animal models of Alzheimer's disease.
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.
In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines. These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction.
A new study shows that men are more likely to lose vision as a result of a particular cause of intracranial hypertension, or increased pressure in the brain, than women with the condition. The research is published in the October 15, 2008, online issue of Neurology, the medical journal of the American Academy of Neurology.
› Verified 6 days ago